Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Candriam S.C.A.

Candriam S.C.A. lifted its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 100.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 269,729 shares of the company’s stock after buying an additional 134,950 shares during the period. Candriam S.C.A.’s holdings in Immunocore were worth $9,799,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after buying an additional 311 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after acquiring an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Immunocore in the 2nd quarter valued at about $42,000. Osaic Holdings Inc. boosted its position in shares of Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after purchasing an additional 1,700 shares in the last quarter. Finally, State of Tennessee Department of Treasury acquired a new position in shares of Immunocore in the 2nd quarter worth approximately $132,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Down 1.3%

Shares of NASDAQ:IMCR opened at $32.82 on Wednesday. The firm has a 50 day simple moving average of $34.61 and a 200 day simple moving average of $34.36. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $40.71. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The company has a market cap of $1.66 billion, a PE ratio of -57.58 and a beta of 0.78.

Wall Street Analysts Forecast Growth

IMCR has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, February 4th. Morgan Stanley lifted their price target on shares of Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Wells Fargo & Company assumed coverage on Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $60.40.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.